Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1983;80(3):279-83.
doi: 10.1007/BF00436170.

Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type

I Bergman, G Bråne, C G Gottfries, K G Jostell, I Karlsson, L Svennerholm

Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type

I Bergman et al. Psychopharmacology (Berl). 1983.

Abstract

Alaproclate, a specific inhibitor of neuronal serotonin re-uptake, was given to 12 patients with dementia of Alzheimer type. The drug was rapidly absorbed and an elimination half-life of 7.1 +/- 0.9 h (+/- SD, n = 8) was calculated. Plasma protein binding for alaproclate was 82 +/- 1%. Two weeks of repeated administration produced plasma concentrations of alaproclate similar to those predicted from a single dose. The pharmacological effect of the drug was demonstrated by an inhibition of serotonin uptake in the patients' platelets and a reduction of the serotonin concentration in blood. Global rating of clinical efficacy showed a positive effect of alaproclate in five of the patients, mainly regarding emotional functions.

PubMed Disclaimer

References

    1. Biochem Med. 1970 Apr;3(5):426-31 - PubMed
    1. Clin Pharmacol Ther. 1982 Apr;31(4):522-7 - PubMed
    1. Adv Biochem Psychopharmacol. 1980;23:295-304 - PubMed
    1. J Neural Transm. 1984;59(4):265-88 - PubMed
    1. Psychopharmacology (Berl). 1980 Jan;67(1):1-7 - PubMed

Publication types

LinkOut - more resources